Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1304395
Abstract: Abstract Objectives: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK,… read more here.
Keywords: per responder; top glargine; cost per; responder ... See more keywords
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2070428
Abstract: ABSTRACT Background Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking. Research design and methods To assess the cost per responder of adalimumab biosimilars versus the… read more here.
Keywords: cost per; responder; cost; adalimumab biosimilars ... See more keywords
A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13635
Abstract: To compare the cost‐effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder reported in randomized controlled trials (RCTs) from the… read more here.
Keywords: cost per; korean perspective; ankylosing spondylitis; per responder ... See more keywords
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10050646
Abstract: Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per… read more here.
Keywords: cost per; secukinumab; responder; secukinumab versus ... See more keywords